State Street
GLUE icon

State Street’s Monte Rosa Therapeutics GLUE Stock Holding History

State Street’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$90.3M Buy
3,731,416
+377,436
+11% +$7.13M ﹤0.01% 1544
2026
Q1 		$55.2M Buy
3,353,980
+1,246,500
+59% +$23.8M ﹤0.01% 1683
2025
Q4 		$33M Buy
2,107,480
+1,260,707
+149% +$17M ﹤0.01% 1983
2025
Q3 		$6.27M Buy
846,773
+14,954
+2% +$79.2K ﹤0.01% 2896
2025
Q2 		$3.75M Buy
831,819
+30,562
+4% +$136K ﹤0.01% 3061
2025
Q1 		$3.72M Sell
801,257
-275,173
-26% -$1.69M ﹤0.01% 2994
2024
Q4 		$7.47M Buy
1,076,430
+388,853
+57% +$2.92M ﹤0.01% 2776
2024
Q3 		$3.64M Buy
687,577
+51,493
+8% +$260K ﹤0.01% 3100
2024
Q2 		$2.38M Buy
636,084
+20,833
+3% +$106K ﹤0.01% 3254
2024
Q1 		$4.34M Buy
615,251
+41,842
+7% +$248K ﹤0.01% 2985
2023
Q4 		$3.24M Sell
573,409
-19,349
-3% -$75.9K ﹤0.01% 3137
2023
Q3 		$2.84M Sell
592,758
-2,277
-0.4% -$14.7K ﹤0.01% 3177
2023
Q2 		$4.08M Buy
595,035
+64,289
+12% +$416K ﹤0.01% 3094
2023
Q1 		$4.13M Buy
530,746
+13,370
+3% +$93K ﹤0.01% 3062
2022
Q4 		$3.94M Buy
517,376
+32,805
+7% +$273K ﹤0.01% 3134
2022
Q3 		$3.96M Buy
484,571
+33,707
+7% +$310K ﹤0.01% 3170
2022
Q2 		$4.36M Buy
450,864
+81,296
+22% +$817K ﹤0.01% 3160
2022
Q1 		$5.18M Buy
369,568
+169,992
+85% +$2.36M ﹤0.01% 3164
2021
Q4 		$4.08M Buy
199,576
+48,034
+32% +$1.01M ﹤0.01% 3340
2021
Q3 		$3.38M Buy
+151,542
New +$4.34M ﹤0.01% 3434

Other funds holding GLUE

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VVM
Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return

State Street's GLUE Position: Q2 2026 in Review

State Street increased its Monte Rosa Therapeutics (GLUE) stake by 11% in Q2 2026, buying an estimated $7.13M and bringing the position to 3,731,416 shares worth $90.3M. The position accounts for ﹤0.01% of the portfolio, ranked #1544.

State Street first reported a position in GLUE in Q3 2021 and has held it in 20 quarters since. 193 funds tracked by Wall St. Rank hold GLUE as of Q2 2026.

  • State Street held 3,731,416 shares of Monte Rosa Therapeutics worth $90.3M as of Q2 2026.
  • State Street bought 377,436 Monte Rosa Therapeutics shares in Q2 2026, an estimated $7.13M.
  • Monte Rosa Therapeutics made up ﹤0.01% of State Street's portfolio in Q2 2026, its #1544 holding.
  • State Street first reported a position in Monte Rosa Therapeutics in Q3 2021 and has held it in 20 quarters since.
  • 193 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q2 2026.

Based on State Street's 13F filing for Q2 2026, filed 7 Aug 2026.